Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nimodipine in migraine: clinical efficacy and endocrinological effects.

Literature DB >> 1782981

Nimodipine in migraine: clinical efficacy and endocrinological effects.

R Formisano¹, P Falaschi, R Cerbo, A Proietti, T Catarci, R D'Urso, C Roberti, V Aloise, F Chiarotti, A Agnoli.

Abstract

Serum prolactin is increased during chronic flunarizine treatment of patients suffering from migraine. In order to clarify the role of calcium in control of the secretion of anterior pituitary hormones, a study has now been made of the effects of chronic nimodipine and propranolol treatment of migraine patients on prolactin (PRL), luteinizing hormone (LH) and growth hormone (GH) levels. 11 patients were treated with nimodipine and 8 with propranolol for four months. A statistically significant reduction in the frequency of the attacks was demonstrated in both groups. No significant change was found in the hormones levels during nimodipine treatment.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1991 PMID： 1782981 DOI： 10.1007/BF00280110

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

9 in total

1. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

Authors:
Journal: Cephalalgia Date: 1988 Impact factor: 6.292

2. Thyrotropin-releasing hormone stimulation of thyrotropin secretion is suppressed by calcium ion antagonists that block transmembrane influx and intracellular mobilization of calcium ion in human subjects.

Authors: M Yamada; M Mori; M Yamaguchi; H Akiyama; S Shiono; I Kobayashi; S Kobayashi
Journal: J Endocrinol Invest Date: 1986-06 Impact factor: 4.256

3. Stroke in migraine as a consequence of propranolol.

Authors: A Bardwell; J A Trott
Journal: Headache Date: 1987-07 Impact factor: 5.887

4. Anterior pituitary hormone secretion during treatment with flunarizine in migrainous patients.

Authors: R Cerbo; R Formisano; P Falaschi; M G Buzzi; A Proietti; G Cusimano; C Roberti; G Di Cesare; A Agnoli
Journal: Clin Neuropharmacol Date: 1988-06 Impact factor: 1.592

5. Nimodipine versus flunarizine in common migraine: a controlled pilot trial.

Authors: G Bussone; S Baldini; G D'Andrea; A Cananzi; F Frediani; L Caresia; F Ferro Milone; A Boiardi
Journal: Headache Date: 1987-02 Impact factor: 5.887

6. Migraine and cluster headache treatment with calcium antagonists supports a vascular pathogenesis.

Authors: J S Meyer; M Nance; M Walker; W J Zetusky; R E Dowell
Journal: Headache Date: 1985-10 Impact factor: 5.887

7. Movement disorders and depression due to flunarizine and cinnarizine.

Authors: F E Micheli; M M Pardal; R Giannaula; M Gatto; I Parera; G Paradiso; M Torres; R Pikielny; J Pardal
Journal: Mov Disord Date: 1989 Impact factor: 10.338

8. Flunarizine-induced parkinsonism in the elderly.

Authors: F Benvenuti; A Baroni; S Bandinelli; L Ferrucci; R Corradetti; T Pantaleo
Journal: J Clin Pharmacol Date: 1988-07 Impact factor: 3.126

9. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man.

Authors: J D Veldhuis; J L Borges; C R Drake; A D Rogol; D L Kaiser; M O Thorner
Journal: J Clin Endocrinol Metab Date: 1985-01 Impact factor: 5.958